Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

BackgroundBiosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in h...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Chamberlain, Bernhard Hemmer, Josef Höfler, Hendrik Wessels, Oliver von Richter, Cyrill Hornuss, Johann Poetzl, Karsten Roth
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
natalizumab
multiple sclerosis
neutralizing antibodies
anti-drug antibodies
immunology
biologic products
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1414304/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1414304/full

Similar Items